Completed PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT00093756

Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

Phase I/II Study of PS-341 in Combination With Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non-small Cell Lung Cancer (NSCLC)

Sponsor: National Cancer Institute (NCI)

Conditions Recurrent Non-small Cell Lung Cancer Stage IIIA Non-small Cell Lung Cancer Stage IIIB Non-small Cell Lung Cancer

Interventions 3-dimensional conformal radiation therapy bortezomib carboplatin paclitaxel

Updated 8 times since 2017 Last updated: Nov 2, 2017 Started: Sep 30, 2004 Primary completion: Jan 31, 2012 Completion: May 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Recurrent Non-small Cell Lung Cancer and Stage IIIA Non-small Cell Lung Cancer and is currently completed. National Cancer Institute (NCI) leads this study, which shows 8 recorded versions since 2004 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1_PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE1_PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1_PHASE2

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alexandria, United States , Anderson, United States , Ann Arbor, United States , Anthony, United States , Aurora, United States , Bismarck, United States , Bloomington, United States , Brainerd, United States , Burnsville, United States , Canton, United States and 75 more locations